What's Happening?
Precision Biologics Manufacturing, a subsidiary of New Horizon Medical Solutions, has announced the groundbreaking of a new manufacturing facility in Southern Nevada. This facility is set to develop advanced biologics technology and is expected to create between 200 to 300 jobs in the Las Vegas Valley by the second half of 2026. The groundbreaking ceremony took place on September 30, 2025, and was attended by biologics executives, local politicians, and team members from New Horizon Medical Solutions. The facility will be GMP-compliant and will focus on expanding U.S.-based biologics production. This development is part of New Horizon's strategy to strengthen its position as a leader in advanced biologics and wound care.
Why It's Important?
The establishment of this facility is significant for the U.S. healthcare and manufacturing sectors, particularly in Nevada. It represents a substantial investment in local manufacturing, which is expected to bolster the local economy by creating hundreds of jobs. The facility will also support the medical ecosystem in Southern Nevada, potentially leading to thousands of additional jobs. This aligns with the state's long-term goals of expanding its medical market and supporting local communities. The facility will serve as a hub for advanced engineering, development, testing, and production, which could enhance the U.S.'s capabilities in biologics and medical solutions.
What's Next?
As the facility becomes operational, it is expected to contribute significantly to the local economy and the medical industry. New Horizon Medical Solutions plans to use the facility as a foundational technology center, which will support training and compliance across the company and the industry. The expansion of biologics production in the U.S. could lead to further innovations in wound care and medical solutions, potentially improving patient outcomes nationwide. The development also aligns with the growth of local institutions like UNLV and the Kirk Kirkorian School of Medicine, which could foster further collaboration and innovation in the medical field.
